CTIS2023-506294-36-00进行中（未招募）1 期
A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) - D798EC00001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,145
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Participant must be = 18 years of age, at the time of signing the ICF., Histologically or cytologically documented locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, oral cavity, or larynx with no evidence of metastatic disease (i.e. M0)., Confirmed unresected Stage III, Stage IVA or IVB according to the eighth edition of the American Joint Committee on Cancer (AJCC) staging manual (tumor, node, metastasis (TNM) staging system)., Participants will have completed definitive concurrent chemoradiotherapy (cCRT) with curative intent within 12 weeks prior to randomization.
排除标准
- •Histologically/cytologically confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including participants with squamous cell carcinoma of unknown primary or non-squamous histologies (eg, nasopharynx or salivary gland). Participants with >1 primary tumors are not eligible for the study., Participants with any of the following: (a) Residual disease that needs further treatment with curative intent after definitive cCRT administration; (b) LA-HNSCC that was resected before definitive cCRT (c) LA-HNSCC that was treated and is recurrent at the time of screening, Participants who have received radiotherapy (RT) alone as definitive local therapy for LA-HNSCC., Receipt of the last dose of anticancer therapy (chemotherapy and/or RT) > 12 weeks (84 days) prior to randomization.
研究者
相似试验
进行中（未招募）
1 期
This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder CancerEUCTR2018-001811-59-FRAstraZeneca AB1,050
进行中（未招募）
1 期
This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder CancerPatients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladderMedDRA version: 21.0Level: PTClassification code 10005010Term: Bladder cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10005011Term: Bladder cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001811-59-PLAstraZeneca AB1,050
进行中（未招募）
1 期
This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder CancerPatients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladderCTIS2023-510015-19-00AstraZeneca AB1,055
进行中（未招募）
1 期
This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder CancerEUCTR2018-001811-59-ESAstraZeneca AB1,050
进行中（未招募）
1 期
This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder CancerPatients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladderMedDRA version: 21.0Level: PTClassification code 10005010Term: Bladder cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10005011Term: Bladder cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001811-59-NLAstraZeneca AB1,050